Venus Concept Inc VERO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERO is a good fit for your portfolio.
News
-
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
-
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
-
Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
-
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
-
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
-
Venus Concept Launches “NEXThetics” Program
-
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $0.84
- Day Range
- $0.72–0.86
- 52-Week Range
- $0.60–4.70
- Bid/Ask
- $0.75 / $0.96
- Market Cap
- $4.83 Mil
- Volume/Avg
- 18,975 / 623,230
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.06
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 304
- Website
- https://www.venusconcept.com
Valuation
|
Metric
|
VERO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.06 |
Price/Cash Flow | — |
Price/Earnings
VERO
Financial Strength
|
Metric
|
VERO
|
|---|---|
Quick Ratio | 1.15 |
Current Ratio | 2.13 |
Interest Coverage | −4.39 |
Quick Ratio
VERO
Profitability
|
Metric
|
VERO
|
|---|---|
Return on Assets (Normalized) | −30.98% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −33.60% |
Return on Assets
VERO
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Qvqslgm | Kfjyfj | $185.8 Bil | |
SYK
| Stryker Corp | Pkwfypcv | Lxbt | $127.4 Bil | |
MDT
| Medtronic PLC | Pmfvwlk | Ydrdyfn | $105.2 Bil | |
BSX
| Boston Scientific Corp | Swqffwbbq | Nrysc | $99.0 Bil | |
DXCM
| DexCom Inc | Kprnqysqxg | Kpxp | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Wxtysmpqp | Kgpqyh | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Sfkdbyvwb | Xqw | $25.0 Bil | |
ALGN
| Align Technology Inc | Hqxfrpxl | Gpywg | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Htgtcqlfy | Bcrhn | $18.9 Bil | |
PODD
| Insulet Corp | Gcnpqpzpl | Xddzpc | $11.7 Bil |